这个注射液竞争是有多么激烈？已有56家药企过评并拥有生产批文！

Core Viewpoint - The article highlights the significant market potential and competitive landscape of Dihydroxypropyl Theophylline Injection, which has shown impressive sales growth and is becoming a target for centralized procurement in China [3][4][10]. Group 1: Product Information - Dihydroxypropyl Theophylline Injection is a smooth muscle relaxant belonging to theophylline class, widely used for treating bronchial asthma, bronchitis, and emphysema [3]. - The original manufacturer of Dihydroxypropyl Theophylline is Japan's Eisai, but the original brand is not available in the domestic market, leading to a dominance of domestic generic drugs [4]. Group 2: Market Performance - In 2023, the sales of Dihydroxypropyl Theophylline Injection in hospitals across China exceeded 250 million yuan, marking a year-on-year growth of 107.2% [4]. - In the first two quarters of 2024, the sales already surpassed 110 million yuan, indicating strong market potential [4]. Group 3: Competitive Landscape - The leading company in the market is Suicheng Pharmaceutical, holding a market share of 19.65% [5]. - A total of 55 companies have successfully passed evaluations and obtained production licenses, while 36 companies are currently under review for production [5]. Group 4: Procurement and Pricing - Dihydroxypropyl Theophylline Injection has been included in centralized procurement initiatives, with the lowest bid price dropping below 1 yuan per unit [10]. - In the 2023 procurement led by Henan, the lowest bid was 0.78 yuan per unit, with other selected prices not exceeding 1 yuan [10]. Group 5: Future Outlook - The ongoing centralized procurement policies and increasing market competition will significantly impact the pricing and market dynamics of Dihydroxypropyl Theophylline Injection [11].